Morphological features of the intestinal mucosa in ulcerative colitis in various forms of the disease




ulcerative colitis, morphological examination, morphometry


Background. Chronic inflammatory bowel disease (CIBD) is one of the most complex nosological groups in gastroenterology, due to the constant increase in their prevalence, shif­ting the onset to an earlier age, increasing the frequency of severe complicated forms. The most common representative of CIBD is nonspecific ulcerative colitis (UC). At the heart of UC is a diffuse ulcerative-inflammatory lesion of the colon. The leading role in the diagnosis of UC belongs to the comparison of the results of endoscopic and morphological methods of research. The morphological method of colonobiopsy examination in UC is the gold standard of diagnosis and makes it possible to determine the signs of disease activity even in endoscopic remission. In contrast to descriptive histology, pathological anatomy, quantitative morphology complements and clarifies the data of studies conducted by conventional morphological methods from the standpoint of generalized approaches. The purpose of quantitative morphology is the maximum objectification of the study of qualitative and quantitative manifestations of pathological processes, nosological units, their pathogenesis, morphogenesis, as well as the exclusion of measurement errors and, as far as possible, the subjectivity of the researcher. The purpose of the study: to conduct a comparative histological examination of biopsies of the mucous membrane of the colon in patients with UC of different severity of the disease. Materials and methods. Histological examination of intestinal biopsy specimens was performed in 55 patients with ulcerative colitis. Patients were divided according to the severity of the disease. Group I (n = 11) — mild form, group II (n = 39) — moderate form and group III (n = 5) — patients with severe UC. Results. In 63.6 % with a mild severity of UC edema was not observed, the condition of the epithelium was unchanged, the architecture is not disturbed. Crypt abscesses were detected in 54.6 % of cases, atrophic changes — in 90.9 %. Inflammatory infiltrate consisted mainly of neutrophils ((176.0 ± 8.22) per 1 mm2 stroma) and mononuclear cells ((232.4 ± 22.83) per 1 mm2 stroma), which indicates the activation of regenerative functions of the mucous membrane. From morphometric measurements the highest indicator was the height of the crypt epithelium (38.3 ± 1.49) μm. With an moderate degree of UC in 33.3 % of cases there was a violation of the integrity of the epithelium, atrophic changes were diagnosed in 23.1 % of cases, violations of crypt architecture — in 17.9 %, the presence of crypt abscesses — 48.8 %, edema — 64.1 %. Morphometric measurement of intestinal mucosal biopsies with moderate severity of UC showed the highest crypt depth (452.6 ± 8.12) μm, crypt epithelial height (42.3 ± 0.33) μm and the number of goblet cells (26.6 ± 1.43). The height of the crypt epithelium was positively correlated with the number of goblet cells (r = 0.30; p < 0.05). Erosions, general epithelial disorders, crypt abscesses, and atrophic changes were observed in the majority of patients with severe UC in 40 %. In severe UC, the smallest crypt depth (426.1 ± 22.37) μm, crypt epithelial height (36.0 ± 2.57) μm, the number of goblet cells (10.5 ± 1.04) and the largest epithelial thickness were observed (51.5 ± 2.81) μm. Conclusions. The pre­sence of crypt abscesses was mainly observed in the group of mild and moderate forms of the disease. Mucosal edema was more common in the group with moderate severity disease. Increased numbers of eosinophils and neutrophils were observed in the group with severety disease.


Download data is not yet available.


Click B, Anderson AM, Koutroubakis IE, et al. Peripheral Eosinophilia in Patients With Inflammatory Bowel Disease Defines an Aggressive Disease Phenotype. Am J Gastroenterol. 2017 Dec;112(12):1849-1858. doi:10.1038/ajg.2017.402.

Gordon IO, Agrawal N, Willis E, et al. Fibrosis in ulcerative colitis is directly linked to severity and chronicity of mucosal inflammation. Aliment Pharmacol Ther. 2018 Apr;47(7):922-939. doi:10.1111/apt.14526.

Kaplan GG, Ng SC. Understanding and Preventing the Global Increase of Inflammatory Bowel Disease. Gastroenterology. 2017 Feb;152(2):313-321.e2. doi:10.1053/j.gastro.2016.10.020.

González-Castro AM, Martínez C, Salvo-Romero E, et al. Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in irritable bowel syndrome. J Gastroenterol Hepatol. 2017 Jan;32(1):53-63. doi:10.1111/jgh.13417.

Windsor JW, Kaplan GG. Evolving epidemiology of IBD. Curr Gastroenterol Rep. 2019;21(8):40. doi:10.1007/s11894-019-0705-6.

Dmochowska N, Wardill HR, Hughes PA. Advances in imaging specific mediators of inflammatory bowel disease. Int J Mol Sci. 2018 Aug 21;19(9):2471. doi:10.3390/ijms19092471.

Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017 Dec 23;390(10114):2769-2778. doi:10.1016/S0140-6736(17)32448-0.

Yalchin M, Baker AM, Graham TA, Hart A. Predicting colorectal cancer occurrence in IBD. Cancers (Basel). 2021 Jun 10;13(12):2908. doi:10.3390/cancers13122908.

Lampinen M, Fredricsson A, Vessby J, et al. Downregulated eosinophil activity in ulcerative colitis with concomitant primary sclerosing cholangitis. J Leukoc Biol. 2018 Jul;104(1):173-183. doi:10.1002/JLB.3MA0517-175R.

Choi EK, Appelman HD. Chronic colitis in biopsy samples: is it inflammatory bowel disease or something else? Surg Pathol Clin. 2017 Dec;10(4):841-861. doi:10.1016/j.path.2017.07.005.

Alpert L, Yassan L, Poon R, et al. Targeted mutational analysis of inflammatory bowel disease-associated colorectal cancers. Hum Pathol. 2019 Jul;89:44-50. doi:10.1016/j.humpath.2019.04.013.

Amcoff K, Cao Y, Zhulina Y, Lampinen M, Halfvarson J, Carlson M. Prognostic significance of faecal eosinophil granule proteins in inflammatory bowel disease. Scand J Gastroenterol. 2019 Oct;54(10):1237-1244. doi:10.1080/00365521.2019.1670251.

Mao R, Rimola J, Chen MH, Rieder F. Intestinal fibrosis: The Achilles heel of inflammatory bowel diseases? J Dig Dis. 2020 Jun;21(6):306-307. doi:10.1111/1751-2980.12876.

Sairenji T, Collins KL, Evans DV. An update on inflammatory bowel disease. Prim Care. 2017 Dec;44(4):673-692. doi:10.1016/j.pop.2017.07.010.

Henriksen M, Høivik ML, Jelsness-Jørgensen LP, Moum B; IBSEN Study Group. Irritable bowel-like symptoms in ulcerative colitis are as common in patients in deep remission as in inflammation: results from a population-based study [the IBSEN Study]. J Crohns Colitis. 2018 Mar 28;12(4):389-393. doi:10.1093/ecco-jcc/jjx152.

Hu X, Deng Q, Ma L, et al. Meningeal lymphatic vessels regulate brain tumor drainage and immunity. Cell Res. 2020 Mar;30(3):229-243. doi:10.1038/s41422-020-0287-8.

Filippone RT, Sahakian L, Apostolopoulos V, Nurgali K. Eosinophils in inflammatory bowel disease. Inflamm Bowel Dis. 2019 Jun 18;25(7):1140-1151. doi:10.1093/ibd/izz024.

Ocansey DKW, Zhang L, Wang Y, et al. Exosome-mediated effects and applications in inflammatory bowel disease. Biol Rev Camb Philos Soc. 2020 Oct;95(5):1287-1307. doi:10.1111/brv.12608.

Jacobs I, Ceulemans M, Wauters L, et al. Role of eosinophils in intestinal inflammation and fibrosis in inflammatory bowel disease: an overlooked villain? Front Immunol. 2021 Oct 19;12:754413. doi:10.3389/fimmu.2021.754413.

Snisarevsky PP. Modern morphological diagnostics of ulcerative colitis and irritable bowel syndrome: histological, histochemical and immunohisto chemical criteria. Wiad Lek. 2021;74(3):381-387. doi:10.36740/WLek202103101.

Mosli MH, Parker CE, Nelson SA, et al. Histologic scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Database Syst Rev. 2017 May 25;5(5):CD011256. doi:10.1002/14651858.CD011256.pub2.

Wang Z, Adachi S, Kong L, et al. Role of eosinophils in a murine model of inflammatory bowel disease. Biochem Biophys Res Commun. 2019 Mar 26;511(1):99-104. doi:10.1016/j.bbrc.2019.02.056.

Ocansey DKW, Pei B, Xu X, Zhang L, Olovo CV, Mao F. Cellular and molecular mediators of lymphangiogenesis in inflammatory bowel disease. J Transl Med. 2021 Jun 10;19(1):254. doi:10.1186/s12967-021-02922-2.

Misselwitz B, Juillerat P, Sulz MC, Siegmund B, Brand S; Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More. Digestion. 2020;101(Suppl 1):69-82. doi:10.1159/000507782.

Sammarco G, Varricchi G, Ferraro V, et al. Mast cells, angiogenesis and lymphangiogenesis in human gastric cancer. Int J Mol Sci. 2019 Apr 29;20(9):2106. doi:10.3390/ijms20092106.



How to Cite

Gaydar, Y., Stoikevich, M., Mylostуva D., & Tarasova, T. (2022). Morphological features of the intestinal mucosa in ulcerative colitis in various forms of the disease. GASTROENTEROLOGY, 56(2), 95–102.



Original Researches